Key Points {#FPar1}
==========

Channeling bias exists in the dispensing of single-ingredient paracetamol versus ibuprofen. In previously published papers, models attempting to control for such channeling may not have adequately controlled for this bias.Propensity score model diagnostics and negative control outcomes can be used to check the adequacy of models to control for channeling bias.Large-scale propensity score matching can reduce channeling bias and should be considered for bias reduction in future observational studies in which the possibility of channeling bias is a major concern.

Introduction {#Sec1}
============

Over-the-counter analgesics such as paracetamol and ibuprofen are among the most widely used drugs in the world. Therefore, having a good understanding of their safety profile is an important public health consideration. A key challenge to studying the safety of paracetamol and ibuprofen is that they are used primarily without prescription, therefore exposure status can be difficult to ascertain accurately in both prospective and retrospective epidemiology studies. Several observational studies have been conducted that attempt to estimate the risks associated with the use of paracetamol \[[@CR1]--[@CR8]\], but all acknowledge the inherent limitations of observational studies in this context. One approach that has been taken \[[@CR7]\] is to use electronic medical records that capture prescriptions, and attempt to estimate the risks using only prescription exposure to paracetamol compared with prescription exposure to other pain medication, such as ibuprofen. While this approach may have promise, a threat to the validity of this design is channeling bias, also called selection by contraindication, i.e. the notion that patients may be systematically exposed to one drug or the other, based on current and past comorbidities, in a manner that could affect the estimates of relative risk.

This study aims to examine whether channeling bias exists in the context of studies that compare paracetamol with ibuprofen, and, if so, the extent to which various confounding adjustment strategies can mitigate this bias when estimating average treatment effects. We do so using the Clinical Practice Research Datalink (CPRD) database, which was the basis of a study \[[@CR7]\] that found an association between paracetamol and increased risk of several adverse events, including upper gastrointestinal (GI) bleeding, myocardial infarction (MI), stroke, and acute renal failure. That study adjusted its estimates for several potential confounders and clearly acknowledged the possibility of confounding by indication (actually, contraindication in this instance), but did not document the existence of this bias or attempt to assess its impact.

The primary research question addressed in the current study is whether evidence of channeling bias in the prescription of single-ingredient paracetamol versus single-ingredient ibuprofen can be detected in an electronic medical records database. If so, a second research question assessed the prospects for studies confronted with that bias to reliably control it through multivariable methods or propensity score adjustment methods that assume the groups being compared are drawn from a single population.

Methods {#Sec2}
=======

We used two approaches to determine if there was evidence of bias. In the first, we looked for evidence that patients who received paracetamol were more likely to have had specific prior diagnoses of interest, including GI bleeding, MI, ischemic or hemorrhagic stroke, or acute or chronic renal disease, than those who received ibuprofen. These are known risks associated with ibuprofen, therefore the question is whether doctors selectively prescribe paracetamol to individuals for whom ibuprofen would be less appropriate. Second, we conducted a more global assessment of bias through the use of propensity score distributions to demonstrate the extent of differences between the populations exposed to these two drugs in terms of their propensity to be prescribed paracetamol versus ibuprofen. Finally, we examined the degree to which channeling bias could be controlled via propensity score matching. To do this, we fitted logistic regression models of negative control outcomes to propensity score matched, paracetamol-exposed and ibuprofen-exposed groups. For the comparison of these groups, we identified negative control outcomes, conditions chosen specifically because they were evaluated a priori to not have a differential risk associated with either OTC analgesic, i.e. conditions for which the relative risk associated with paracetamol versus ibuprofen was therefore believed to be approximately one. In this analysis, successful control of channeling by the propensity score matching would be evidenced by the lack of association of the negative control outcomes with the exposure group, i.e. by observing no more negative controls associated with the exposure group than would be expected to be observed by chance. The criteria for defining these negative controls are described below. The protocol for this study is available at ClinicalTrials.gov (NCT identifer: NCT02830178).

Database Used {#Sec3}
-------------

The CPRD, a UK primary care database containing de-identified data from 1 January 1988 through 31 December 2014 and covering 11.65 million individuals, was used for these analyses. The database includes data on demographics, conditions diagnosed, observations, measurements, and procedures that the general practitioner (GP) is made aware of, in addition to any made by the GP. A key strength of the data is the long-term follow-up. Overall, median follow-up time for individual patients is approximately 5 years (interquartile range 1.8--11.1 years) \[[@CR9]\]. Data for this study were from practices classified as 'up to standard' (UTS) by the CPRD during the period of interest. The UTS designation reflects a minimum, practice-level measure of quality based on continuity of recording and number of deaths recorded. The protocol for this study (reference number 15_173R) was approved by the Independent Scientific Advisory Committee (ISAC).

Determination of Exposures and Outcomes {#Sec4}
---------------------------------------

The CPRD data in this analysis were converted to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) version 5 \[[@CR10]\]. The OMOP CDM allows for standardization of clinical structure and content across databases, and also facilitates the development of covariates in the large-scale propensity score models. Native source codes for outcomes and comorbid conditions are mapped to the OMOP standardized vocabularies for each domain (conditions, procedures, etc.). For instance, all Read condition codes (diagnoses, procedures, and clinical observations) are mapped to SNOMED-CT concepts, and Gemscript drug codes are mapped to RxNorm codes \[[@CR10]\].

Cohort Definition {#Sec5}
-----------------

For subjects included in the study, the index date was defined as the day when they received a first prescription for single-ingredient paracetamol and/or single-ingredient ibuprofen. Subjects were included if they were aged 18 years or older on the index date and enrolled in an UTS practice for the 2 years prior to and 1 year following the index date. To reduce the risk of observing prevalent prescription use, we required at least 6 months of continuous observation without prescriptions prior to the first prescriptions of paracetamol or ibuprofen in 2012. Only index dates in 2012 were considered. In addition, subjects with a prescription for paracetamol- or ibuprofen- containing combination medication on the index date were excluded.

We classified analgesic use into two cohorts: (1) 'any paracetamol', i.e. patients with new paracetamol exposure alone or in combination with a new ibuprofen exposure; and (2) 'ibuprofen alone', i.e. patients with new, single-ingredient ibuprofen alone. Where multiple exposures on the index date qualified a patient for inclusion, cohort and index date assignment were based on the qualifying exposure(s) occurring on the index date only. Approximately 6% of the cohort had concomitant use and were classified as 'any paracetamol', to better reflect prescribing in clinical practice. A sensitivity analysis excluding concomitant users, to assess the impact of these users on the evidence of channeling, was performed.

Statistical Methods Used {#Sec6}
------------------------

### Channeling Bias Models {#Sec7}

To gain an understanding of how the study populations differ from each other, a descriptive comparison by 10-year age group, sex, and baseline health-related characteristics was performed, stratified by prescriptions for any paracetamol versus ibuprofen, and age 18 years or older in 2012 (see the 'Before Match' columns of Table [1](#Tab1){ref-type="table"}).Table 1Distribution of selected characteristics 1 year prior to first use of paracetamol and ibuprofen in 2012 among users in the study populations before and after matching on the publication variables PS model and the large-scale PS modelBefore match (*N* *=* 143,126)After matched on variables in the publication variables PS model (*N* *=* 98,048)After matched on variables in the large-scale PS model (*N* *=* 66,070)Paracetamol, %Ibuprofen, %Std diff^a^Paracetamol, %Ibuprofen, %Std diff^a^Paracetamol, %Ibuprofen, %Std diff^a^Female60.659.10.02959.861.1−0.02660.060.4%−0.008Mean age, years (SD)62.2 (19.6)52.6 (18.3)--56.1 (19.0)55.8 (18.7)--56.4 (19.2)57.3 (19.2)--Age, years 15--191.63.1−0.0982.42.40.0012.62.30.016 20--243.25.5−0.1154.64.60.0014.64.50.005 25--293.55.4−0.0914.84.80.0024.64.30.011 30--344.05.9−0.0905.45.5−0.0035.25.00.009 35--394.06.3−0.1055.35.4−0.0025.14.90.008 40--444.88.0−0.1346.46.40.0016.45.80.023 45--495.49.1−0.1467.27.20.0027.16.60.018 50--545.88.8−0.1187.57.30.0057.26.90.011 55--596.28.0−0.0727.57.50.0007.27.10.005 60--648.89.9−0.03810.110.4−0.01010.09.90.003 65--6910.710.00.02111.211.6−0.01111.411.6−0.005 70--7410.37.40.1029.59.9−0.0149.510.1−0.020 75--7911.05.90.1848.08.1−0.0048.49.2−0.027 80--849.83.80.2415.55.20.0156.06.5−0.023 85--897.01.90.2493.02.60.0233.13.5−0.019 90--943.30.70.1851.21.00.0151.31.4−0.012 95--990.80.10.1010.20.10.0120.20.20.007Conditions Obese4.03.30.0403.83.60.0073.73.7−0.001 Smoker8.37.70.0228.77.90.0288.38.30.000 Osteoarthritis of the knee15.19.00.18811.611.30.01211.912.5−0.021 Neoplasm of the prostate1.40.80.0540.91.1−0.0211.21.2−0.003 Hyperthyroidism0.60.50.0150.50.5−0.0010.50.5−0.005 Inflammatory bowel disease0.20.20.0040.10.2−0.0090.10.2−0.009 Rheumatoid arthritis1.80.70.0911.30.90.0331.11.2−0.005 Heart failure1.20.30.1060.50.40.0200.50.50.003 Ischemic heart disease4.92.00.1562.92.80.0062.93.1−0.011 Essential hypertension29.017.50.27521.121.6−0.01021.923.2−0.033 Hyperlipidemia5.33.40.0924.14.2−0.0064.14.3−0.008 Cerebrovascular disease1.90.50.1240.90.70.0190.70.9−0.022Drugs Cardiac glycosides2.30.50.1510.80.70.0150.90.9−0.005 Corticosteroids, systemic23.819.10.11520.521.5−0.02621.121.5−0.009 Antibacterials, systemic53.146.90.12350.151.2−0.02249.950.8−0.018 Proton-pump inhibitors36.928.80.17532.432.40.00032.032.9−0.019 Angiotensin system29.517.90.27721.822.1−0.00722.523.8−0.031 Non-ibuprofen NSAIDs29.820.00.22826.026.9−0.02123.724.5−0.018 Other analgesics39.920.80.42428.028.2−0.00527.829.7−0.042 Anxiolytics8.26.10.0837.37.30.0006.87.1−0.014 Hypnotics and sedatives9.86.90.1058.18.4−0.0118.18.4−0.010 Statins32.519.50.30024.224.6−0.01024.426.0−0.038 Vitamin K antagonists5.41.50.2172.62.00.0372.42.5−0.010*PS* propensity score, *Std diff* standardized difference, *NSAIDs* non-steroidal anti-inflammatory drugs^a^The difference in prevalence of the characteristics in the two cohorts divided by the standard deviation

We examined potential channeling bias in the prescription of any paracetamol versus ibuprofen. We used multivariable logistic regression with any paracetamol versus ibuprofen as the outcome, and diagnoses of GI bleeding, MI, ischemic or hemorrhagic stroke, or acute or chronic renal disease as the 'exposure' (predictor) variable, controlling for age group in 5-year increments and sex. The presence or absence of a given diagnosis was determined by diagnoses in the database for the 2 years prior to the index date (date of the first paracetamol/ibuprofen prescription).

### New-User Cohort Analysis Using Propensity Scores {#Sec8}

A comparative cohort analysis was performed, comparing new users of paracetamol with new users of ibuprofen. Two propensity score models were created, both with any paracetamol use (yes/no) as the 'outcome' variable. For the first propensity score model, the independent variables were baseline patient characteristics defined as described in previous studies described in the literature \[[@CR1]--[@CR5], [@CR7]\]. These covariates, which we will refer to as 'publication covariates', were not consistently included in each study, but represent a super-set of the covariates measured, and include the following conditions and drug exposures (the number of studies that included the variable is given in parentheses): obese (6), morbidly obese (6), smoker (5), alcohol abuser (5), upper GI events (1), osteoarthritis (1), rheumatoid arthritis (1), ischemic heart disease (3), heart failure (2), hypertension (7), cerebrovascular disease (1), diabetes mellitus (4), hyperthyroidism (1), stroke or transient ischemic attack (1), cancer \[excluding non-melanoma skin cancer\] (1), inflammatory bowel (1), autoimmune disease (1), depression (1), drug abuse (1), anticoagulants (1), oral glucocorticoids (1), diuretics (2), cardiac glycosides (1), statins (2), angiotensin receptor blockers (3), hypnotics and anxiolytics (1), antipsychotics (1), antibacterials (1), aminosalicylates (1), antidepressants (1), aspirin (2), oral corticosteroids (1), proton-pump inhibitors (1), histamine-2 receptor antagonists (1), hyperlipidemia (2), non-ibuprofen non-steroidal anti-inflammatory drugs (2), and other analgesics (5).

For the second propensity score model, a much larger set of baseline covariates were defined, which we will refer to as the 'full set of covariates available' or 'large-scale propensity score covariates':Age in 5-year incrementsSexRaceYear of index dateMonth of index dateCharlson Comorbidity IndexDiabetes Complications Severity Index (DCSI) scoreCHADS2 score

*Conditions* [1](#Fn1){ref-type="fn"} Presence/absence of a condition in a 365-day window prior to or on the index datePresence/absence of a condition in a 30-day window prior to or on the index datePresence/absence of a condition diagnosed in an inpatient setting in a 180-day window prior to or on the index datePresence/absence of an aggregation of episodes of care over time for a condition ('condition era') any time prior to or on the index datePresence/absence of a condition era that overlaps the index dateCondition classes (based on the SNOMED hierarchy of conditions)Presence/absence of a drug in a 365-day window prior to or on the index datePresence/absence of a drug in a 30-day window prior to or on the index date

*Drugs* [2](#Fn2){ref-type="fn"} Presence/absence of an inference of length of time of exposure to a drug product ('drug era') for all in a 365-day window prior to or on the index datePresence/absence of a drug era in a 30-day window prior to or on the index datePresence/absence of a drug era that overlaps the index datePresence/absence of a drug era that overlaps the index datePresence/absence of a drug era any time prior to or on the index dateDrug classes based on the Anatomical Therapeutic Chemical hierarchy

*Procedures, observations and measurements* [3](#Fn3){ref-type="fn"} Presence/absence of a procedure in a 365-day window prior to or on the index datePresence/absence of a procedure in a 30-day window prior to or on the index dateProcedures classes (based on the SNOMED hierarchy of procedures)Presence/absence of an observation in a 365-day window prior to or on the index datePresence/absence of an observation in a 30-day window prior to or on the index dateCount of each observation concept in a 365-day window prior to or on the index datePresence/absence of a measurement in a 365-day window prior to or on the index datePresence/absence of a measurement in a 30-day window prior to or on the index dateCount of each measurement concept in a 365-day window prior to or on the index datePresence/absence of a measurement with a numeric value below the normal range for the latest value within 180 days of the cohort indexPresence/absence of a measurement with a numeric value above the normal range for the latest value within 180 days of the cohort indexCounts of the number of concepts that a person has within each domain (i.e. condition, drug, procedure, clinical observation, laboratory measurement)

All propensity models were fitted using regularized regression with an L~1~ (LASSO) prior \[[@CR11]\]. The optimal regularization hyperparameters were estimated using tenfold cross-validation. Based on the work of Walker et al. \[[@CR12]\], we estimated preference scores, which are propensity scores normalized for the prevalence of the drugs being compared. The state of clinical equipoise between different treatments exists when the treatments are considered equivalent and there is no clinical reason for choosing one treatment over another. Walker et al. \[[@CR12]\] suggested the use of a minimum threshold of 50% of subjects from each population with preference scores between 0.3 and 0.7 to provide evidence of clinical equipoise. We compared the preference scores for the probability of exposure to a first prescription for any paracetamol versus ibuprofen alone using these guidelines.

We examined the standardized mean differences (SMDs) for both the publication covariates and the full set of available covariates between paracetamol and ibuprofen in the two propensity score models. SMDs are a measure of covariate balance between the two treatment groups and are the difference in prevalence in each cohort divided by the standard deviation of the difference. A large absolute value SMD on a covariate is an indication of a significant disparity in the proportion of subjects with the covariate between the two groups. An SMD \> 0.1 has been used as an ad hoc heuristic for what constitutes 'large' \[[@CR13]\].

Negative Control Outcomes Analyses for Residual Confounding {#Sec9}
-----------------------------------------------------------

Negative controls are outcomes determined a priori to have no association with the exposure of interest \[[@CR14]\]. In particular, there must be no mention of these outcomes in the US FDA-structured product drug label for either paracetamol or ibuprofen, a manual review of the literature must find no studies showing the drug causing the outcome, and the drugs cannot be listed as a 'causative agent' for the outcome according to data provided in *Drug-Induced Diseases: Prevention, Detection and Management* \[[@CR15]\]. The resulting list contained 31 outcomes. Schuemie et al. \[[@CR16]\] determined that a sample size of at least 25 negative controls is sufficient for constructing an empirical null distribution. Any measurement error in the negative controls is intended to shape, at least in part, the empirical distribution.

Models with these negative controls as outcome variables (outcome models), which adequately control for systematic bias, should produce relative risk estimates close to the null value of 1.0. Negative control models allow for the examination of the extent of bias in the database, study design and analysis, to the degree that they produce significant odds ratios (ORs) different from 1.0. We fit a series of logistic regression models to examine the association between treatment with paracetamol or ibuprofen for each of the 31 negative control incident outcomes within 1 year after the index date for treatment. Review of all available time prior to the outcome was the constraint in determining whether an event was incident or not. The negative controls chosen for this study were:Melanocytic nevus of skinImpotenceLipomaLabyrinthitisPanic attackAcute stress disorderChronic sinusitisSeborrheic keratosisInfected ulcer of skinBronchopneumoniaRestless legsPerforation of tympanic membraneType 1 diabetes mellitusHemangiomaLichen planusOcular hypertensionBronchiectasisHyperthyroidismLymphedemaObsessive-compulsive disorderVitiligoStrabismusOpen-angle glaucomaBiliary calculusLactose intolerancePtosis of eyelidUrethritisKeratoacanthomaVasomotor rhinitisGranuloma annularePhobic disorder

For each of the negative control outcomes, we fit six models:*Demographic Adjustment in Outcome Model*: Performed a multivariable logistic regression to estimate the effect of exposure (any paracetamol versus ibuprofen) on the incidence of each outcome, adjusting for sex and age in 5-year increments. No matching or restriction (via propensity score or otherwise) was performed prior to final outcome model fitting.*Publication Variable Outcome Model Adjustment*: Performed a multivariable logistic regression to estimate the effect of exposure (any paracetamol versus ibuprofen) on the incidence of each outcome, adjusting for sex, age in 5-year increments, and the set of 38 publication covariates. No matching or restriction (via propensity score or otherwise) was performed prior to final outcome model fitting.*Large-Scale Adjusted Outcome Model* Performed a regularized logistic regression using L~1~ (LASSO) shrinkage \[[@CR11]\] to estimate the effect of exposure (any paracetamol versus ibuprofen) on the incidence of each outcome, adjusting for the full set of data covariates available. No shrinkage was applied to the effect of exposure, and no matching or restriction (via propensity score or otherwise) was performed prior to final outcome model fitting.*Publication Variable Propensity Score Adjustment* Performed a multivariable logistic regression to estimate a propensity score that predicts treatment assignment (any paracetamol versus ibuprofen) using baseline covariates for sex, age in 5-year increments, and publication variables. One-on-one matching on the propensity score was performed using a standardized caliper of 0.25\*propensity score standard deviation. The matched sets were used within a univariate conditional logistic regression, which estimated the effect of exposure (any paracetamol versus ibuprofen) on the incidence of each outcome, without further adjustment.*Large-Scale Propensity Score Adjustment* Performed a regularized logistic regression using L~1~ shrinkage \[[@CR11]\] to estimate a propensity score that predicts treatment assignment (any paracetamol versus ibuprofen) using the full set of data covariates available. The propensity score was used to perform 1:1 matching (using a standardized caliper of 0.25 × propensity score standard deviation). The matched sets were used within a univariate conditional logistic regression, which estimated the effect of exposure (any paracetamol versus ibuprofen) on the incidence of each outcome, without further adjustment.*Large-Scale Propensity Score Adjustment with Large-Scale Outcome Modeling* Performed a regularized logistic regression using L~1~ shrinkage which estimated a propensity score that predicts treatment assignment (any paracetamol versus ibuprofen) using the full set of data covariates. The propensity score was used to perform 1:1 matching (using a standardized caliper of 0.25 × propensity score standard deviation). The matched sets were then used to perform a regularized conditional logistic regression using L~1~ shrinkage to estimate the effect of exposure (any paracetamol versus ibuprofen) on the incidence of each outcome, adjusted for the full set of data covariates available. No shrinkage was applied to the effect of exposure.

We analyzed each of the negative controls to determine the level of bias remaining in the six different models. If there was no residual bias in a particular model, we would expect no more than one or two risk ratios to be significantly greater or less than unity based on a *p* value of \<0.05 (i.e. 5% of 31 ≈ 1.5, the number of significant parameter estimates found by 5% chance alone).

Results {#Sec10}
=======

The number of participants in the CPRD dataset eligible for inclusion in the study was 3,949,187 (Fig. [1](#Fig1){ref-type="fig"}), of whom 144,337 received prescriptions for paracetamol or ibuprofen (Fig. [1](#Fig1){ref-type="fig"}). Prior to any matching, more females received either prescription than males, and those receiving ibuprofen prescriptions were somewhat younger than those prescribed paracetamol (Table [1](#Tab1){ref-type="table"}). The paracetamol cohort had higher rates of cardiovascular and musculoskeletal morbidity. Smoking and obesity were also more prevalent in the paracetamol group (Table [1](#Tab1){ref-type="table"}).Fig. 1Flow of patients from Clinical Practice Research Datalink to analytic study population. *CPRD* Clinical Practice Research Datalink, *yo* years old, *combo* combination

Regarding evidence of channeling, approximately 13% of patients who received a prescription for any paracetamol had a prior condition of GI bleed, MI, renal disease and/or stroke in the 2 years prior to the prescription (Table [2](#Tab2){ref-type="table"}). In those patients prescribed ibuprofen, approximately 6% had a prior condition of GI bleed, MI, renal disease and/or stroke in the 2 years prior to the prescription. The ORs comparing prior conditions in those prescribed any paracetamol versus ibuprofen were all significantly greater than unity for all of the conditions, both in the unadjusted models and the models adjusted for sex and age (Table [2](#Tab2){ref-type="table"}). For those patients prescribed any paracetamol, the odds of prior MI were approximately 2.6 times the odds of prior MI in those prescribed ibuprofen, after adjusting for sex and age (adjusted OR 2.6, 95% confidence interval \[CI\] 2.3--3.0). Similarly, the OR of a GI bleed prior to paracetamol prescription versus an ibuprofen prescription was 1.4 (95% CI 1.3--1.5), OR of renal disease was 1.8 (95% CI 1.7--1.9), and OR of a stroke was 2.1 (95% CI 1.9--2.3). For MI, renal disease and stroke, the adjustment for sex and age moved the OR toward unity, reflecting the preferential prescription of paracetamol in patients over 70 years of age (Table [1](#Tab1){ref-type="table"}). If the assumption of clinical equipoise were valid, the ORs for each of these conditions would not differ from unity.Table 2Unadjusted and adjusted OR of prior conditions for patients prescribed any paracetamol versus ibuprofen alone and paracetamol only versus ibuprofen only (*N* *=* 144,337)ConditionAny paracetamol^a^ \[% (*N*)\]Ibuprofen \[% (*N*)\]Unadjusted OR (95% CI)Adjusted OR^b^ (95% CI)GI bleed3.1 (2372)2.2 (1480)1.5 (1.4--1.6)1.4 (1.3--1.5)MI1.6 (1175)0.4 (288)3.7 (3.3--4.2)2.6 (2.3--3.0)Renal disease7.4 (5643)2.8 (1887)2.8 (2.7--3.0)1.8 (1.7--1.9)Stroke2.5 (1874)0.7 (494)3.5 (3.2--3.8)2.1 (1.9--2.3)Paracetamol onlyIbuprofen onlyUnadjusted OR (95% CI)Adjusted OR^b^ (95% CI)GI bleed3.3 (2201)2.2 (1480)1.5 (1.4--1.6)1.5 (1.4--1.6)MI1.7 (1149)0.4 (288)4.1 (3.6--4.7)2.9 (2.5--3.3)Renal disease8.0 (5382)2.8 (1887)3.1 (2.9--3.2)1.9 (1.8--2.1)Stroke2.7 (1791)0.7 (494)3.8 (3.4--4.2)2.3 (2.0--2.5)*OR* odds ratio, *CI* confidence interval, *GI* gastrointestinal, *MI* myocardial infarction^a^Any paracetamol includes patients who received both paracetamol and ibuprofen on the index date^b^Adjusted by age group and sex

Table [2](#Tab2){ref-type="table"} also presents the corresponding information for paracetamol only versus ibuprofen only, omitting those patients who were prescribed both ibuprofen and paracetamol on their index date. The impact of excluding those with both was small but consistent. Both the crude and age- and sex-adjusted ORs were higher without the concomitant group than including it with those receiving paracetamol.

Propensity Score Models {#Sec11}
-----------------------

We developed two propensity score models to assess the differences between using the covariates described in prior literature (the 'publication covariates') versus the full set of data covariates available. The area under the receiver operating characteristics curve (AUC) for the propensity scores based on 'publication covariates' was 0.71, while the AUC for the full set of data covariates available was 0.85. The full set of covariates provided better discrimination between patients receiving paracetamol and those receiving ibuprofen compared with the publication covariates. The larger AUC found using the full set of covariates is an indication that discrimination between subjects receiving prescriptions for paracetamol and ibuprofen is achievable and is further evidence that the two treatments do not follow the assumption of clinical equipoise.

The distributions of the preference scores for paracetamol and ibuprofen utilizing the publication covariates are shown in Fig. [2](#Fig2){ref-type="fig"}a. The overlap in the preference scores in the 0.3--0.7 range, as described by Walker et al. \[[@CR12]\], was \>50% for the publication covariates (Table [3](#Tab3){ref-type="table"}). Using this set of covariates would fulfill the criteria for necessary overlap to assume clinical equipoise for the two treatment options. However, when utilizing the full set of covariates (Fig. [2](#Fig2){ref-type="fig"}b), the degree of overlap was below 50% and is evidence against the assumption of clinical equipoise for paracetamol and ibuprofen prescriptions. While matching by preference scores using the published covariates reduced the number of eligible matches by approximately 32% (See Supplement for sample attrition table), matching on the full set of available covariates reduced the eligible matches by over 50%.Fig. 2Distribution of propensity scores from **a** publication covariates and **b** the full set of covariates for any paracetamol compared with ibuprofen Table 3Propensity score models distribution between 0.3 and 0.7AnalgesicAll scores0.3 ≤ preference ≤ 0.7*NN*%Publication variables model Any paracetamol75,91951,24967.5 Ibuprofen alone68,41849,72872.7Large-scale model Any paracetamol75,91930,21939.8 Ibuprofen alone68,41826,06438.1

The change in covariate balance for the publication covariates between paracetamol and ibuprofen following propensity score matching using publication covariates for a representative negative outcome---melanocytic nevus of skin---is shown in Fig. [3](#Fig3){ref-type="fig"}a. Each point represents the (absolute value) SMD for a single covariate prior to matching (on the horizontal axis) and after matching (on the vertical axis). Prior to matching, the SMDs ranged from −0.15 to 0.40 in the publication covariates, indicating appreciable differences in the distributions of these covariates between the paracetamol and ibuprofen populations. Following matching, among the matched cohorts, the SMDs ranged from −0.02 to 0.01, indicating more homogenous populations (Fig. [3](#Fig3){ref-type="fig"}a).Fig. 3Absolute value standardized difference of the mean of the **a** publication covariates and **b** full set of data covariates available prior to and after matching on publication variable propensity scores, and **c** full set of data covariates available prior to matching and after matching on propensity scores using the full set of data covariates available for melanocytic nevus of skin

The purpose of propensity score matching is to achieve a balanced sample on all sample characteristics. Figure [3](#Fig3){ref-type="fig"}b shows the covariate balance before and after matching on the publication variables propensity score model, but showing the covariate balance among the full set of available covariates. While all SMDs for the publication covariates were reduced to below 2% after matching by the publication covariates, there were a large number (nearly 200) of other covariates for which the SMD between paracetamol and ibuprofen subjects remained \>0.10 after matching. This indicates that there were still many covariates that were unbalanced between the two treatment groups, and brings into question the assumption of clinical equipoise for the treatments. Figure [3](#Fig3){ref-type="fig"}c, in which subjects were matched by propensity scores developed from the full set of covariates available, demonstrates that the full set of covariates achieved adequate balance after matching.

Residual Confounding in Negative Controls {#Sec12}
-----------------------------------------

As shown in Table [4](#Tab4){ref-type="table"}, in our examination of residual bias in the six models for our negative controls, we found that only those models matched on all available covariates (models 5 and 6) removed confounding bias sufficiently to ensure that any significant finding would likely be due to chance as opposed to being due to residual bias. All models without matching performed poorly, presumably due to the lack of balance in the clinical characteristics of the sample. In model 5, where we performed univariable logistic regression (with exposure as the single variable) after 1:1 matching by a propensity score developed using all available covariates, no risk ratios in the 31 negative controls differed significantly from unity. By comparison, in model 4, where we performed univariate logistic regression after 1:1 matching on propensity scores developed using the publication covariates, we found seven risk ratios out of 31 negative controls (approximately 23%) that differed significantly from unity. We also found no risk ratios different from unity in model 6, where we matched by propensity score using all available covariates and used a logistic regression model that also adjusted for all available covariates.Table 4Negative control model point estimates and confidence intervalsModel 1\
Demographic adjustmentModel 2\
Publication variables adjustmentModel 3\
Large-scale adjustmentModel 4\
Publication variables propensity score matchedModel 5\
Large-scale propensity score matchedModel 6\
Large-scale propensity score matched and adjustmentNo. of negative controls significant737700Negative association313500Positive association424200No. not significant242824243121Fraction significant, %22.69.722.622.60.00.0OutcomeRR (95% CI)RR (95% CI)RR (95% CI)RR (95% CI)RR (95% CI)RR (95% CI)Acute stress disorder1.13 (0.8--1.61)0.98 (0.52--2.10)1 (0.71--1.41)0.88 (0.60--1.28)1.13 (0.73--1.74)0.96 (0.54--1.68)Biliary calculus1.34 (0.8--2.58)1.19 (0.71--2.35)1.14 (0.97--1.34)**1.20 (1.01--1.42)**0.95 (0.77--1.17)0.95 (0.74--1.21)Bronchiectasis1.31 (0.9--2.02)1.09 (0.78--1.56)1.18 (0.88--1.61)1.21 (0.86--1.70)1.1 (0.75--1.6)0.75 (0.27--2.18)Bronchopneumonia**2.71 (1.41--5.61)2.71 (1.41--5.61)2.25 (1.15--4.76)**1.90 (0.90--4.25)0.75 (0.25--2.16)NAChronic sinusitis0.96 (0.55--1.68)0.98 (0.65--1.64)1.1 (0.87--1.39)1.07 (0.82--1.39)1.2 (0.89--1.62)1.42 (0.95--2.16)Granuloma annulare1.65 (0.63--4.8)1.65 (0.63--4.80)0.93 (0.72--1.2)1.40 (0.45--4.73)1.26 (0.88--1.81)1.19 (0.73--1.93)Hemangioma0.65 (0.42--2.22)0.63 (0.34--2.82)0.96 (0.69--1.33)1.00 (0.69--1.45)0.94 (0.58--1.53)0.97 (0.59--1.61)Hyperthyroidism1.06 (0.58--1.82)0.93 (0.45--2.17)0.96 (0.72--1.3)0.88 (0.62--1.25)0.82 (0.54--1.24)0.74 (0.43--1.23)Impotence1.07 (0.91--1.26)0.89 (0.79--1.01)0.93 (0.52--1.83)0.89 (0.79--1.00)1.09 (0.94--1.27)1.06 (0.78--1.43)Infected ulcer of skin**5.41 (1.47--34.7)5.41 (1.47--34.74)5.41 (1.47--34.74)**4.00 (1.00--26.50)4.00 (0.59--78.2)NA^a^Keratoacanthoma1.42 (0.73--3.02)1.39 (0.60--4.74)**2.04 (1.11--3.96)**1.25 (0.59--2.72)1.78 (0.8--4.2)NA^a^Labyrinthitis0.72 (0.43--1.58)0.67 (0.31--1.65)**0.74 (0.61--0.89)0.70 (0.57--0.85)**0.82 (0.64--1.05)0.8 (0.61--1.05)Lactose intolerance1.08 (0.33--3.75)1.08 (0.33--3.75)1.08 (0.33--3.75)1.33 (0.29--6.77)2.00 (0.53--9.48)NA^a^Lichen planus0.85 (0.58--1.28)0.76 (0.34--1.80)0.82 (0.56--1.19)0.83 (0.56--1.24)1.13 (0.7--1.84)1.34 (0.63--2.76)Lipoma**0.76 (0.59--0.99)**0.72 (0.42--1.19)**0.75 (0.61--0.93)0.74 (0.59--0.92)**0.81 (0.62--1.06)0.86 (0.65--1.15)Lymphedema**1.93 (1.4--2.82)**1.57 (0.76--3.23)**1.47 (1.05--2.1)1.48 (1.02--2.16)**1.33 (0.85--2.11)1.78 (0.76--4.45)Melanocytic nevus of skin**0.82 (0.73--0.92)**0.76 (0.49--1.18)**0.87 (0.76--0.98)0.79 (0.69--0.90)**0.98 (0.83--1.15)0.97 (0.81--1.16)Obsessive-compulsive disorder0.79 (0.47--1.31)0.80 (0.27--2.79)0.92 (0.54--1.57)1.05 (0.57--1.92)1.00 (0.5--2.01)NA^a^Ocular hypertension0.88 (0.55--1.45)0.86 (0.57--1.33)0.86 (0.61--1.2)0.94 (0.64--1.39)0.73 (0.44--1.19)0.71 (0.36--1.36)Open-angle glaucoma0.81 (0.56--1.17)0.81 (0.45--1.58)0.92 (0.65--1.3)0.85 (0.57--1.26)0.87 (0.54--1.38)0.6 (0.01--43.54)Panic attack1.01 (0.84--1.24)0.84 (0.65--1.11)0.81 (0.31--2.33)0.84 (0.69--1.03)0.81 (0.64--1.04)0.83 (0.53--1.31)Perforation of tympanic membrane0.68 (0.35--2.67)0.75 (0.27--2.97)0.9 (0.61--1.32)0.75 (0.50--1.13)1.13 (0.7--1.82)1.7 (0.66--4.55)Phobic disorder1.01 (0.79--1.32)0.85 (0.42--1.90)0.93 (0.72--1.2)0.94 (0.71--1.24)1.08 (0.77--1.53)1.05 (0.6--1.87)Ptosis of eyelid1.18 (0.66--2.16)0.94 (0.46--4.02)1.15 (0.65--2.09)0.89 (0.46--1.72)1.64 (0.78--3.58)NA^a^Restless legs1.34 (1--1.92)1.11 (0.51--3.01)1.18 (0.92--1.53)1.03 (0.78--1.37)1.13 (0.8--1.58)0.94 (0.54--1.6)Seborrheic keratosis**0.83 (0.73--0.96)0.84 (0.76--0.95)**1.02 (0.67--1.71)**0.87 (0.79--0.97)**1.04 (0.91--1.18)1.03 (0.88--1.2)Strabismus0.99 (0.55--1.8)0.99 (0.55--1.80)0.99 (0.55--1.8)0.80 (0.37--1.71)0.73 (0.28--1.8)NA^a^Type 1 diabetes mellitus**1.46 (1.1--1.95)**0.98 (0.64--1.60)1.01 (0.73--1.4)0.95 (0.67--1.35)0.76 (0.5--1.16)0.84 (0.05--10.69)Urethritis0.53 (0.2--4.19)0.90 (0.39--2.10)0.9 (0.39--2.1)0.80 (0.31--2.03)0.6 (0.12--2.45)NA^a^Vasomotor rhinitis0.54 (0.18--1.95)0.64 (0.32--1.25)0.68 (0.34--1.34)**0.24 (0.07--0.64)**0.67 (0.22--1.85)NA^a^Vitiligo0.82 (0.43--1.52)0.82 (0.43--1.52)0.83 (0.43--1.6)1.00 (0.49--2.06)1.00 (0.41--2.44)NA^a^Bolded values indicate RR significantly different from 1.0*RR* relative risk, *CI* confidence interval, *NA* not available^a^ Outcome model was attempted but had insufficient counts to make an estimate

It should be noted that in model 6, using both propensity score matching and a fully adjusted outcome model, we were unable to model 10 of the negative controls. This was due to the methodological constraint that to fit the full outcome model, we needed to perform regularization. To perform regularization, we needed to know the appropriate hyperparameter (variance of the regularization prior) to use, and for that we used cross-validation. We required a minimum amount of data for the cross-validation (100 'informative strata', which is basically the same as the number of outcome events in the two treatment cohorts taken together), and ten of the negative controls did not meet this criterion.

Discussion {#Sec13}
==========

This is the first study that we know of to examine evidence directly and quantitatively for channeling in the use of paracetamol and ibuprofen, two widely used analgesics. The purpose of this study was to answer two questions. First, was there evidence of channeling in the prescription of paracetamol versus ibuprofen, and, if so, could we adequately adjust for channeling in studies examining outcomes after exposure?

We found that patients with a prescription of single-ingredient paracetamol were more likely to have a prior history of GI bleeding, MI, renal disease, and stroke compared with ibuprofen after controlling for age and sex. Given this evidence of preferential prescribing, we explored whether various strategies for confounding adjustment in observational studies were adequate to allow for unbiased assessments of outcomes from these exposures. We used propensity score adjustment as it is designed to control for systematic differences in patient populations between those receiving a treatment and a comparator.

When we constructed a propensity score model using baseline characteristics previously used in prior published studies, we found that propensity score matching did adequately balance these covariates but failed to balance other observable covariates. This suggests that current publications may still be subject to channeling bias that could influence reported effect estimates. Moreover, while the publication-inspired propensity score distributions may suggest that the two populations may be sufficiently near clinical equipoise, we showed that a more complete confounding adjustment would result in much greater discrimination between the two populations that calls clinical equipoise into question. When we applied a large-scale regularized model to estimate the propensity score using all available covariates, we observed that matching achieved consistently greater balance across all covariates, inclusive of the baseline characteristics used in prior publications. These findings suggest that the magnitude and complexity of channeling bias is substantial, and while it may not be adequately mitigated with traditional approaches, could be better managed through more complete multivariable models combined with matching.

Negative control outcomes were selected a priori, meeting criteria for having no known association with exposure to paracetamol or ibuprofen. The distribution of relative risk estimates from negative control outcomes provides a measure of the extent of residual bias after controlling for possible confounders since we know these should produce relative risk estimates near unity. We selected 31 negative control outcomes to empirically evaluate the expectation that (under the null hypothesis), 5% of the relative risks would be statistically significantly different from 1.0 (at *α* = 0.05), by chance alone. When we only used publication variables in the propensity score model, we observed there was substantial residual bias, resulting in the model failing to have nominal operating characteristics; namely, 23% (7 of 31) of the negative control outcomes yielded significant findings, with five of the null outcomes showing significant decreased risk associated with paracetamol, and two outcomes showing an increased risk. For many of the negative controls, paracetamol looks numerically protective, indicating that we cannot make assumptions about direction of the bias when we do not adjust properly. These results call into question whether statistical significance under this adjustment strategy can be confidently inferred without calibration \[[@CR16]\]. In contrast, when we fit the propensity score model using a larger set of covariates, all significant associations observed using literature covariates were attenuated; no negative control outcomes produced significant findings after full propensity score matching. The negative control results corroborate the covariate balance findings, which showed that modeling limited to publication covariates left residual bias, but more complete adjustment with matching appears to be effective at mitigating the threats of channeling, although at the cost of reducing the degree of overlap in propensity score distributions between the cohorts.

This assessment of channeling bias has important limitations that require consideration. The bias evaluation using negative controls requires an exchangeability assumption that may not hold for future unknown outcomes of interest. Specifically, we assume the magnitude (but not specific source) of residual bias for the unknown outcome could have been sampled from the distribution of residual bias that was observed for the negative controls. As such, it is possible there is additional residual bias that we did not adequately observe based on the measured covariate balance and empirical null distribution diagnostics. This analysis was restricted to prescription use of paracetamol and ibuprofen, and it is unknown whether these results would generalize to non-prescription exposures. There are several reasons for a GP to prescribe these medications in the CPRD, including record keeping and giving the patient access to the medication at a lower cost because the patient qualifies for free filling of prescriptions. In addition, those using these medications chronically may need larger quantities than typically available over the counter. Thus, it is likely that, by relying on prescriptions, we skewed our study population toward elderly subjects with chronic conditions who may also be at the low end of the economic spectrum. While being selected into the study population limits the generalizability of the results, it does not limit their validity, i.e. we expect that the selection mechanism should be the same for both drug cohorts.

Conclusions {#Sec14}
===========

While it is widely understood that there are substantial differences in the baseline characteristics of patients treated with acetaminophen versus ibuprofen, the adjustment for these differences must be confirmed with comparisons before and after matching or with appropriate diagnostics if other methods are used. We were not able to adequately remove selection bias using a selected set of covariates for propensity score adjustment. Large-scale propensity score matching offers a novel approach that should be considered when attempting to mitigate the risk of channeling bias.
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 Examples of conditions include essential hypertension, dyspnea and osteoarthritis.

 Examples of drugs include analgesics, antithrombotic agents, and codeine.

 Examples of a procedure, measurement and observation include heart valve replacement, creatinine measurement and CHADS2 stroke risk score, respectively.
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